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Oxandrolone in trauma patients !
Jane M. Gervasio, Roland N. Dickerson, Jessica Swearingen, Mary E.D. Yates, Ceaminia Yuen, 
Timothy C. Fabian, Martin A. Croce, Rex O. Brown !
Abstract !
Study Objective 
To determine the effect of oxandrolone administration on nutritional and clinical outcomes after 
multiple trauma. !
Design 
Prospective, randomized, double-blind, placebo-controlled study. Setting. Level 1 trauma center 
in a university teaching hospital. 
 
Patients 
Sixty-two patients requiring enteral nutrition, 60 of whom completed the study. 
 
Intervention 
Patients were randomized to receive either oxandrolone 10 mg or placebo twice/day for a 
maximum of 28 days. 
 
Measurements and Main Results 
Total urinary nitrogen, prealbumin, nitrogen balance, total body water, and body cell mass were 
measured on day 1 of enteral nutrition and then at day 7, day 10, and study exit. Patients were 
assessed daily for metabolic and infectious complications. The two groups were similar for 
demographics and dosage of enteral nutrition. Measurement of total urinary nitrogen at study 
entry showed both groups to be highly catabolic (oxandrolone 17.2 ± 4.9, placebo 19.1 ± 10.8 g/
day, NS). On days 7 and 10, total urinary nitrogen increased in both groups; however, there was 
no significant difference between groups. Nitrogen balance was negative throughout the study in 
each group. Body cell mass decreased slightly in both groups over the study period. Prealbumin 
serum concentrations increased significantly in both groups at day 10 and study exit compared 
with study entry. The groups did not differ significantly for length of hospital stay (oxandrolone 
30.8 ± 17.9, placebo 27.0 ± 25.7 days), length of intensive care unit stay (oxandrolone 17.1 ± 
7.8, placebo 15.5 ± 9.7 days), and frequency of pneumonia or sepsis (oxandrolone 48, placebo 43 
episodes). !
Conclusion 
Oxandrolone 20 mg/day does not have obvious benefit in nutritional and clinical outcomes 
during the first month after multiple trauma. !!
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The catabolic response to injury is associated with elevated glucocorticoid, catecholamine, and 
glucagon serum concentrations and a breakdown of body protein. Critical injury causes 
hypermetabolism and hypercatabolism, resulting in an increase in resting energy expenditure and 
decrease in body cell mass.1 Patients sustaining major trauma had a mean body protein loss of 
1.62 kg (16%) over 21 days, with skeletal muscle accounting for the largest percentage.1 
Specialized nutrition support (parenteral, enteral) is given to these patients to minimize this 
protein loss. Quantities as high as 2–3 g/kg/day of protein have been administered in attempts to 
produce net anabolism.2 Although specialized nutrition support improves the quality of patient 
care, it fails to ameliorate net protein catabolism.3 Anabolic agents have been investigated for 
their use in preserving body cell mass and improving muscle strength. Studies in trauma and 
thermally injured patients reported improved nitrogen retention and restored muscle mass, but 
therapy was limited by androgenic complications.4,5 !
Oxandrolone is a testosterone analog with reported anabolic activity 5–10 times that of older 
anabolic agents and with considerably fewer androgenic effects. It improved body cell mass in 
thermally injured patients during the recovery phase6 and restored muscle mass in patients with 
acquired immunodeficiency syndrome.7,8 To our knowledge, no study has investigated 
oxandrolone during the acute phase of injury in trauma patients. We examined the agent’s effects 
on nutritional and clinical outcomes after multiple trauma. !
Methods !
This was a prospective, double-blinded, randomized, placebo-controlled study conducted in a 
level 1 trauma center. It was approved by a university investigational review board and the 
hospital. Written informed consent was obtained from all patients. A total of 62 patients with 
multiple trauma requiring enteral nutrition were randomized by a table of random numbers to 
receive either oxandrolone (Oxandren; BTG Corporation, Iselin, NJ) 10 mg twice/day 
(maximum approved dosage for catabolic patients) or placebo. Patients had to be 18–60 years of 
age, have sustained multiple trauma, and require enteral nutrition. Those who were less than 90% 
of ideal body weight were considered undernourished and those more than 30% of ideal body 
weight were considered obese. Exclusion criteria were renal insufficiency or failure defined by a 
serum creatinine concentration above 2 mg/dl; hepatic insufficiency defined by a total bilirubin 
concentration above 3 mg/dl, or cirrhosis by history or biopsy; gastrointestinal malabsorptive 
disorders, metastatic carcinoma, diabetes mellitus, or human immunovirus (HIV) infection; 
hypersensitivity to anabolic steroids; and pregnancy. !
Injury Severity9 and Trauma10 scores were calculated at hospital admission. Acute Physiology 
and Chronic Health Evaluation II (APACHE II)11 and Glascow Coma Scale12 scores were 
calculated for each patient within the first 24 hours of entering the study. Study entry occurred 
within the first five days after trauma. !
Patients received oxandrolone or placebo for 28 days unless they were discharged or transferred 
to another facility, in which case the drug was discontinued. Oxandrolone tablets or placebo 
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tablets (thiamine 50 mg) were crushed and suspended in water before administration through a 
nasogastric feeding tube or enterostomy. Patients received tablets orally when they were able to 
consume an oral diet. Compliance with therapy was recorded every day. !
Enteral nutrition was administered to each group as an immune-enhancing formula (ImmunAid; 
McGaw Laboratories, Santa Ana, CA) to provide 30 total calories/kg/day and 2.4 g protein/kg/
day while in the intensive care unit (ICU). All patients who were transferred out of the ICU were 
changed to a polymeric, high-protein, fiber-containing enteral formula. Oral diets were 
prescribed as appropriate, and enteral nutrition was discontinued when patients were able to 
consume more than 50% of required calories orally. Patients were monitored daily by the 
nutrition support service for metabolic, gastrointestinal, pulmonary, and mechanical 
complications. Mean daily and mean maximum caloric and protein intake were calculated for 
each group. !
Plasma electrolytes (Na+, K+, Cl-, total CO2, Ca2+, Mg2+, PO43-), blood urea nitrogen (BUN), 
creatinine, prealbumin, albumin, aspartate aminotransferase (AST), total bilirubin, and alkaline 
phosphatase were measured at study admission and days 7, 10, and 28, or study exit if before day 
28. Twenty-four-hour urine samples were collected at study admission and days 7, 10, and 28 or 
study exit for total urinary nitrogen (TUN). A 10-ml aliquot was obtained from the 24-hour urine 
collection and immediately frozen at -20°C. Total urinary nitrogen was determined by 
pyrochemilumenescence. !
Total body water, lean body mass, and body cell mass were calculated by bioelectrical 
impedance analysis on the same schedule. Computerized Bioelectrical Analyzer System (RJL 
System, Inc., Detroit, MI) was used as described previously.13,14 !
Clinical outcome variables including length of ICU stay, hospital stay, and mechanical 
ventilation days were recorded. Patients were assessed daily for infectious complications. 
Infections were determined based on set criteria and defined as pneumonia by bronchial alveolar 
lavage with 105 or more colony-forming units/ml15; sepsis, severe sepsis, septic shock, acute 
respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), and 
systemic inflammatory response syndrome (SIRS) by the American College of Chest 
Physicians–Society of Critical Care Medicine consensus statement16; abdominal infections 
including intraabdominal abscess, necrotizing fasciitis, and peritonitis by positive abdominal 
infection and physical diagnosis; and sinusitis by mucosal thickening, computerized tomographic 
scan, and positive cultures. Infections were verified and documented by a trauma surgical 
physician who was blinded to study therapy. !
Statistical Analysis !
A sample of 30 in each group was estimated to observe a decrease in TUN of 20% from baseline 
to day 7 of the study in patients receiving oxandrolone, with β of 0.8 and α of 0.05. Continuous 
data were analyzed by analysis of variance (ANOVA) with Tukey’s test for post hoc pairwise  
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Table 1. Summary of Group Demographics 
     Oxandrolone (n=30)  Placebo (n=30) 
Age (yrs)    33.9 ± 12.5   35.2 ± 11.0 
M/F     26/4    29/1 
Height (cm)    177.3 ± 6.4   179.1 ± 9.6 
Weight (kg)    83.2 ± 19.4   83.0 ± 18.7 
Ideal body weight (%)   112 ± 22    110 ± 19 
APACHE II score   15.8 ± 5.8   15.5 ± 5.5 
Injury Severity score   27.8 ± 11.3   25.1 ± 13.5 
Trauma score    8.2 ± 3.5   7.8 ± 3.4 
Glasgow Coma Scale score  8.9 ± 5.2   8.3 ± 4.9 
Trauma (blunt/penetrating)  24/6    19/11 
Values are expressed as mean ± SD. !
comparisons. Categoric data were analyzed by 𝓍2 test or Fisher’s exact test. A p value less than 
0.05 was considered statistically significant. All data are expressed as mean ± standard deviation 
(SD). !
Results !
Sixty-two patients were enrolled. Two who were receiving placebo withdrew, leaving 60 patients 
with 30 in each group. One patient withdrew because he believed reinstitution of mechanical 
ventilation was associated with the study. The other patient did not provide a reason for 
withdrawal. The two groups were similar for demographics (Table 1) and administration of 
specialized nutrition support (Table 2). Using admission weight and height, the oxandrolone 
group consisted of 22 normally nourished, 6 obese, and 2 undernourished patients. The placebo 
group had 22 normally nourished, 5 obese, 3 undernourished patients. All patients were entered 
in the study within 1–5 days after injury. !
No statistically significant differences were observed in the number of study days between the 
oxandrolone and placebo group (20.3 ± 8.8 vs 18.1 ± 8.2 days, NS), and each group received 
over 90% of prescribed doses of oxandrolone or placebo. In the oxandrolone group, 22 patients 
were fed by small-bore nasogastric feeding tube, 2 by nasojejunal tube, 5 by jejunostomy tube, 
and 1 by gastrostomy tube. Respective figures in the placebo group were 25, 1, 3, and 1. Eight 
patients in the oxandrolone group and four in the placebo group required parenteral nutrition for 
an average of 8 and 9 days, respectively, secondary to gastrointestinal intolerance to tube 
feedings. The decision to start parenteral nutrition was made jointly between nutrition support 
and trauma teams. Parenteral nutrition consisted of a formulation that was isonitrogenous and 
isocaloric to the immune-enhancing enteral formula. During parenteral nutrition, oxandrolone or 
placebo was given through a nasogastric tube that was clamped for 1 hour after each 
administration. !
Six patients in the oxandrolone group and five in the placebo group received propofol for 
sedation or anxiety. Fat calories from propofol were calculated, and no significant differences  !
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Table 2. Nutrition Support Administration 
       Oxandralone  Placebo 
Length of specialized nutrition support (days)  20.0 ± 8.7  17.4 ± 9.3 
Length of enteral nutrition support (days)   16.4 ± 8.8  14.6 ± 9.3 
Maximum calories received in 1 day (kcal/kg/day)  29.9 ± 10.4  27.4 ± 8.6 
Maximum protein received in 1 day (g protein/kg/day) 2.2 ± 0.7  2.1 ± 0.7 
Nitrogen intake (g/day) 
Day 1       7.9 ± 6.2  8.4 ± 5.8 
Day 7       16.5 ± 10.1  20.6 ± 8.8 
Day 10      16.8 ± 12.6  18.6 ± 10.8 
Day 28 or study exit     16.0 ± 4.8  12.9 ± 10.7 
Total urinary nitrogen excretion (g/day) 
Day 1       17.2 ± 4.8  19.1 ± 10.8 
Day 7       22.2 ± 11.2  28.0 ± 15.5 
Day 10      26.0 ± 11.9  27.1 ± 5.9 
Day 28 or study exit     16.5 ± 7.6  18.3 ± 10.9 
Nitrogen balance (g/day) 
Day 1       -11.4 ± 7.6  -12.8 ± 11.8 
Day 7       -9.5 ± 10.8  -10.9 ± 20.8 
Day 10      -11.8 ± 9.3  -15.1 ± 19.3 
Day 28 or study exit     -3.8 ± 10.6  -6.3 ± 12.5 
Received parenteral nutrition (no.)    8   4 
Values are expressed as mean ± SD. !!
Table 3. Serum Protein Concentrations and Selected Chemistries 
       Oxandrolone  Placebo 
Serum prelbumin concentration (mg/dl) 
Day 1       11.6 ± 3.9  10.1 ± 3.0 
Day 7       14.8 ± 6.2  14.1 ± 7.0 
Day 10      20.9 ± 13.0a  15.8 ± 7.9a 
Day 28 or study exit     30.5 ± 12.7a,b  23.0 ± 7.3a 
Serum albumin concentration (g/dl) 
Day 1       2.3 ± 0.6  2.2 ± 0.6 
Day 7       2.0 ± 0.5  2.2 ± 0.8 
Day 10      2.1 ± 0.6  2.3 ± 1.1 
Day 28 or study exit     2.5 ± 0.6  2.6 ± 0.6 
Serum glucose concentration (mg/dl) 
Day 1       119 ± 24   133 ± 30 
Day 28 or study exit     116 ± 37   116 ± 25 
Blood urea nitrogen (mg/dl) 
Day 1       12.4 ± 5.3  13.9 ± 8.9 
Day 7       20.3 ± 14.5  23.4 ± 14.6 
Day 10      28.9 ± 28  27.7 ± 23.2 
Day 28 or study exit     28.5 ± 40.8  24.5 ± 18.3 
Serum creatinine (mg/dl) 
Day 1       0.9 ± 0.3  0.9 ± 0.2 
Day 7       0.9 ± 0.5  0.9 ± 0.2 
Day 10      1.1 ± 1.3  0.9 ± 0.4 
Day 28 or study exit     1.0 ± 1.0  0.9 ± 0.8 
Data are expressed as mean ± SD. 
ap < 0.05 compared with day 1 concentrations. 
bp < 0.05 between groups. !
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were observed between patients receiving this drug in the two groups (672 ± 358 vs 674 ± 304 
calories/day, NS). !
Measurement of TUN at study entry showed both groups to be highly catabolic. On days 7 and 
10, TUN increased in both groups. Mean TUN decreased by day 28 or study exit. Mean nitrogen 
balance was negative on all study days in both groups. No statistically significant difference 
between groups was seen for any of these values. !
Prealbumin serum concentrations increased significantly in both groups at days 10 and study exit 
compared with study entry (Table 3). The only significant difference between groups was noted 
at study exit. No significant differences were appreciated with serum albumin concentrations or 
serum glucose concentrations within or between groups. There were no significant differences 
between groups in BUN and serum creatinine concentration. Mean BUN concentrations 
approximately doubled in each group from study entrance to exit. Hepatic chemistry values in 
the two groups were total bilirubin concentration (day 1, 0.9 ± 0.7 oxandrolone, 1.0 ± 0.8 g/dl 
placebo; exit, 0.7 ± 0.4 vs 1.0 ± 1.0, NS), AST (day 1, 151 ± 372 vs 77 ± 102 U/ml, NS; exit, 80 
± 64 vs 65 ± 41 U/ml, NS), and alkaline phosphatase (day 1, 54 ± 25 vs 49 ± 15 U/ml, NS; exit, 
115 ± 117 vs 151 ± 69 U/ml, NS). !
Body cell mass decreased slightly in each group (oxandrolone, 33.7 ± 4.6 to 31.8 ± 4.8 kg; 
placebo, 32.6 ± 4.0 to 29.1 ± 3.5 kg); however, no significant differences were observed between 
or within groups (Figure 1). Total body water decreased significantly (p<0.05) in each group 
over the study period (oxandrolone, 58.9 ± 12.5 to 53.3 ± 14.3 L; placebo, 57.8 ± 9.6 to 47.8 ± 
17.0 L). No significant differences between groups were noted in total body water at study entry 
or exit (Figure 2). Complete measurements could be performed in only 15 of 60 patients 
secondary to early hospital discharge or inability to measure due to metal placed on the patient 
(halos, traction). !
No significant difference were seen between groups for length of hospital stay, length of ICU 
stay, and frequency of pneumonia, sepsis, ARDS, or MODS (Table 4). !
Table 4. Clinical Outcomes 
       Oxandrolone  Placebo 
Mean ± SD length of hospital stay (days)   30.8 ± 17.9  27.0 ± 25.7 
Mean ± SD length of ICU stay (days)   17.1 ± 7.8  15.5 ± 9.7 
Mean ± SD length of mechanical ventilation (days)  11.7 ± 8.9  12.6 ± 10.0 
Pneumonia (no. of patients, days)    27, 170   21, 129 
Sepsis (no. of patients, days)    21, 181   22, 180 
Severe sepsis (no. of patients, days)    4, 13   2, 14 
SIRS (days)      283   243 
ARDS (no. of patients)     3   3 
MODS (no. of patients)     2   1 
Death (no. of patients)     3   3 
SIRS = systemic inflammatory response syndome; ARDS = acute respiratory distress syndrome; MODS = multiple 
organ dysfunction syndrome 
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Figure 1. Body cell mass in the 15 patients (8 oxandrolone, 7 placebo) who could have bioelectrical impedance 
analysis done at study entry and at day 28. There was no significant difference between or within groups over time.	

Figure 2. Total body water measurements in the 15 patients who could have bioelectrical impedance analysis done 
at study entry and at day 28. Total body water decreased significantly (p<0.05) in each group over time, but there 
was no significant difference between groups. !!
Discussion !
Oxandrolone is approved for treatment of weight loss from catabolic illness including trauma 
injury. Our investigation of the approved dosage of oxandrolone in trauma patients who were 
given an enteral immune-enhancing diet showed no significant differences in nutritional or 
clinical outcomes compared with patients receiving placebo. Unlike this study, previous studies 
in critically ill patients did not measure clinical outcome; however, our study was not specifically 
powered to show a difference in clinical outcome. Also, our metabolic and nutritional findings 
are in contrast to some reports4,5,17 and in agreement with others.18 !
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A prospective, randomized, double-blind study reported decreased urinary excretion of nitrogen 
and 3-methylhistidine in men receiving nandrolone 50 mg on day 3 and 25 mg on day 6 after 
trauma compared with similar patients receiving placebo.4 These results were supported by a 
prospective, randomized study in patients who received nandrolone 50 mg 3 days after sustaining 
moderate to severe head injury.17 Nitrogen balance improved in patients who received 
intramuscular stanozolol 50 mg 24 hours before colorectal surgery in a prospective, randomized, 
controlled trial.5 Nonseptic patients had significant improvements in body weight, lean body 
mass, and body cell mass when given intramuscular nandrolone 50 mg/week.18 It is interesting 
that septic patients in that prospective, randomized, unblinded study did not have significant 
improvement in nutritional markers. Our patients were acutely ill from multiple trauma when 
they entered the study. Virtually all had SIRS and many had sepsis during the initial weeks of the 
study. Failure of the active drug to affect nutritional measurements early in the hospital course is 
consistent with findings in those septic patients.18 !
All patients in the cited studies received parenteral nutrition initially. In our study, each group 
received enteral nutrition initially and parenteral nutrition only when enteral intolerance was 
documented. Our group and others demonstrated the clinical benefits of enteral nutrition early in 
the clinical course after traumatic injury.19,20 It is also notable that all patients in our study 
received an immune-enhancing enteral formulation that contained supplemental doses of 
arginine, glutamine, and α-linolenic acid. Evidence indicates that clinical outcome after trauma is 
improved when such formulations are administered.21-23 Whereas the number of patients and 
number of days of parenteral nutrition were modestly higher in the oxandrolone group, we do not 
believe that this masked improvement in clinical outcome. It may have been difficult for such 
improvement to be observed in patients receiving oxandrolone because both groups primarily 
were receiving enteral nutrition with an immune-enhancing diet. !
The amount of protein administered also varied between our study and others. In previous 
investigations, patients received approximately 70 g protein/day or 1 g/kg/day. This is similar to 
maintenance dosages required in health (recommended daily allowance 0.8 g/kg/day in the 
United States) rather than what is considered good practice in critically ill patients. Our patients 
had an enteral protein goal of 2.4 g/kg/day, and a substantial number of them attained this goal 
for several days. !
Timing of anabolic steroid administration also may be an issue. Thermally injured patients given 
a high protein diet plus oxandrolone had increased weight gain and improved physical therapy 
index.6 That study was begun when patients began recovery in an inpatient rehabilitation center. 
Another report from the same group described improved nitrogen retention during the acute 
phase of thermal injury in a small number of patients.24 Patients with HIV-related weight loss 
experienced restoration of body cell mass when oxandrolone was given during a program of 
resistance exercise.7 These data suggest that the agent may be most beneficial when given during 
the recovery phase of injury or illness. Because our study was conducted during the acute phase 
after traumatic injury, our patients were definitely hypercatabolic and likely hypermetabolic, 
although energy expenditure was not measured. 
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!
The major effect of oxandrolone during short-term administration is increased net muscle protein 
synthesis.25 If this is also true for acutely ill patients, it may difficult to show improved 
measurements of nutrition in this population due to increased protein synthesis secondary to 
critical illness and administration of an enteral diet containing nutrients such as glutamine and 
arginine that also increase protein synthesis. !
Administration of oxandrolone during the first month after multiple trauma does not result in 
obvious benefit in nutritional and clinical outcomes. !
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